World Kidney Day 2016 focuses on kidney disease in childhood and the antecedents of adult kidney disease that can begin in earliest childhood. Chronic kidney disease (CKD) in childhood differs from that in adults, as the largest diagnostic group among children includes congenital anomalies and inherited disorders, with glomerulopathies and kidney disease in the setting of diabetes being relatively uncommon. In addition, many children with acute kidney injury will ultimately develop sequelae that may lead to hypertension and CKD in later childhood or in adult life. Children born early or who are small-for-date newborns have relatively increased risk for the development of CKD later in life. Persons with a high-risk birth and early childhood history should be watched closely in order to help detect early signs of kidney disease in time to provide effective prevention or treatment. Successful therapy is feasible for advanced CKD in childhood; there is evidence that children fare better than adults, if they receive kidney replacement therapy including dialysis and transplantation, while only a minority of children may require this ultimate intervention. Because there are disparities in access to care, effort is needed so that those children with kidney disease, wherever they live, may be treated effectively, irrespective of their geographic or economic circumstances. Our hope is that World Kidney Day will inform the general public, policy makers and caregivers about the needs and possibilities surrounding kidney disease in childhood.

1.
Goldstein SL: Acute kidney injury in children and its potential consequences in adulthood. Blood Purif 2012;33:131-137.
2.
Harambat J, van Stralen KJ, Kim JJ, Tizard EJ: Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012;27:363-373.
3.
Warady BA, Chadha V: Chronic kidney disease in children: the global perspective. Pediatr Nephrol 2007;22:1999-2009.
4.
Furth SL, et al: Design and methods of the chronic kidney disease in children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 2006;1:1006-1015.
5.
Health Statistics and Information Systems: Estimates for 2000-2012. http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html.
7.
Saran R, et al: US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2015;65:A7.
8.
ESPN/ERA-EDTA Registry: European Registry for Children on Renal Replacement Therapy. http://www.espn-reg.org/index.jsp.
9.
Ardissino G, et al: Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 2003;111(4 pt 1):e382-e387.
10.
Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL: CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis 2012;60:1002-1011.
11.
Global Burden of Disease Study 2013 Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743-800.
12.
Coca SG, Singanamala S, Parikh CR: Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012;81:442-448.
13.
Basu RK, et al: Assessment of worldwide acute kidney injury, renal angina and epidemiology in critically ill children (AWARE): study protocol for a prospective observational study. BMC Nephrol 2015;16:24.
14.
Eckardt KU, et al: Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158-169.
15.
Wuhl E, et al: Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract. Clin J Am Soc Nephrol 2013;8:67-74.
16.
ESCAPE Trial Group, et al: Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009;361:1639-1650.
17.
van Stralen KJ, Borzych-Dużalka D, Hataya H, et al: Survival and clinical outcomes of children starting renal replacement therapy in the neonatal period. Kidney Int 2014;86:168-174.
18.
Querfeld U, et al: The cardiovascular comorbidity in children with chronic kidney disease (4C) study: objectives, design, and methodology. Clin J Am Soc Nephrol 2010;5:1642-1648.
19.
Hoy WE, et al: The early development of the kidney and implications for future health. J Dev Orig Health Dis 2010;1:216-233.
20.
Flynn JT, et al: The effect of abnormal birth history on ambulatory blood pressure and disease progression in children with chronic kidney disease. J Pediatr 2014;165:154-162.e151.
21.
Rodriguez MM, et al: Histomorphometric analysis of postnatal glomerulogenesis in extremely preterm infants. Pediatr Dev Pathol 2004;7:17-25.
22.
Abitbol CL, et al: Long-term follow-up of extremely low birth weight infants with neonatal renal failure. Pediatr Nephrol 2003;18:887-893.
23.
Hodgin JB, Rasoulpour M, Markowitz GS, D'Agati VD: Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009;4:71-76.
24.
Verhave JC, Wetzels JF, van de Kar NC: Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol Dial Transplant 2014;29(suppl 4):iv131-iv141.
25.
Torres VE: Vasopressin receptor antagonists, heart failure, and polycystic kidney disease. Annu Rev Med 2015;66:195-210.
26.
Jarzembowski T, et al: Impact of non-compliance on outcome after pediatric kidney transplantation: an analysis in racial subgroups. Pediatr Transplant 2004;8:367-371.
27.
Watson AR: Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol 2000;14:469-472.
28.
Aujoulat I, et al: Non-adherence in adolescent transplant recipients: the role of uncertainty in health care providers. Pediatr Transplant 2011;15:148-156.
29.
Watson AR, et al: Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA). Kidney Int 2011;80:704-707.
30.
Watson AR, et al: Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA). Pediatr Nephrol 2011;26:1753-1757.
31.
Gallieni M, et al: The burden of hypertension and kidney disease in Northeast India: the institute for Indian mother and child noncommunicable diseases project. ScientificWorldJournal 2014;2014:320869.
32.
White A, Wong W, Sureshkumur P, Singh G: The burden of kidney disease in indigenous children of Australia and New Zealand, epidemiology, antecedent factors and progression to chronic kidney disease. J Paediatr Child Health 2010;46:504-509.
33.
Zarocostas J: Need to increase focus on non-communicable diseases in global health, says WHO. BMJ 2010;341:c7065.
34.
Gulland A: WHO agrees to set up body to act on non-communicable diseases. BMJ 2013;346:f3483.
35.
Feehally J: Chronic kidney disease: health burden of kidney disease recognized by UN. Nat Rev Nephrol 2011;8:12-13.
36.
Couser WG, Remuzzi G, Mendis S, Tonelli M: The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011;80:1258-1270.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.